Evidence map›Paper›PMID 26598017›Full record

ArticleLeukemia2016

Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials.

E Hoster, C H Geisler, J Doorduijn, B van der Holt, J Walewski, J Bloehdorn, V Ribrag, G Salles, M Hallek, C Pott and 11 more

Abstract readComparative StudyLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Hematopoietic cell transplantation for mantle cell lymphoma.International journal of hematology · 2022
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 17 institutions in 8 countries.

E HosterDepartment of Internal Medicine III, University Hospital Munich, Munich, Germany.
C H GeislerHematology Department, Rigshospitalet, Copenhagen, Denmark.
J DoorduijnDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
B van der HoltHOVON Data Center, Erasmus MC Cancer Institute - Clinical Trial Center, Rotterdam, The Netherlands.
J WalewskiDepartment of Lymphoid Malignancies, The Maria Skłodowska-Curie Memorial Institute and Oncology Center, Warsaw, Poland.
J BloehdornDepartment of Internal Medicine III, University of Ulm, Ulm, Germany.
V RibragInstitut Gustave Roussy, Villejuif, France.
G SallesHospices Civils de Lyon, Université Claude Bernard, Pierre Bénite, France.
M HallekDepartment I of Internal Medicine, University of Cologne, Cologne, Germany.
C PottSecond Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
M SzymczykDepartment of Lymphoid Malignancies, The Maria Skłodowska-Curie Memorial Institute and Oncology Center, Warsaw, Poland.
A KolstadOncology Department, The Norwegian Radium Hospital, Oslo, Norway.
A LaurellDepartment of Oncology, Uppsala University Hospital, Uppsala, Sweden.
R RätyDepartment of Hematology, Helsinki University Central Hospital, Helsinki, Finland.
M JerkemanDepartment of Oncology, Skane University Hospital, Lund, Sweden.
M Van't VeerDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
J C Kluin-NelemansDepartment of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
W KlapperDepartment of Pathology, Hematopathology Section and Lymph Node Registry, University of Kiel, Kiel, Germany.
M UnterhaltDepartment of Internal Medicine III, University Hospital Munich, Munich, Germany.
M DreylingDepartment of Internal Medicine III, University Hospital Munich, Munich, Germany.
O HermineDepartment of Hematology, Hôpital Necker, Assistance Publique Hôpitaux de Paris, University Paris Descartes, Paris, France.
Erasmus MC Cancer Institute · NLMünchen Klinik · DEThe Maria Sklodowska-Curie National Research Institute of Oncology · PLHelsinki University Hospital · FIInstitut Gustave Roussy · FRKiel University · DENorwegian Cancer Society · NORigshospitalet · DKSkåne University Hospital · SESorbonne Université · FRUniversität Ulm · DEUniversité Claude Bernard Lyon 1 · FRUniversity Hospital Schleswig-Holstein · DEUniversity Medical Center Groningen · NLUniversity of Cologne · DEUppsala University Hospital · SEZimmer Biomet (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Whole-Body IrradiationAdultAgedAntimetabolites, AntineoplasticChemoradiotherapyCytarabineDose-Response Relationship, DrugHumansLymphoma, Mantle-CellMiddle AgedStem Cell TransplantationAntimetabolites, AntineoplasticCytarabine

Identifiers

PMID26598017
OpenAlexW2174333862

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.